Internal biological phase may determine menopause treatment response
Menopause response types may reflect internal biological phase: randomized timing of sufficiently fast-acting treatments would repeatedly reverse the relative benefit of hormone-based and other treatments. No meaningful phase interaction, or one confined to reports rather than objective physiology, would reject this
Stage of verification
- Hypothesis published2026-10-03
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Indicator or biomarker
Circadian phase
A measure of position within the internal biological daily cycle
Where this hypothesis actsDuring menopause, when internal biological phase may alter responsiveness to endocrine and nonendocrine inputs
Hypotheses on this target 2
Telling states apart1
Direct measurement1
Indicator replacement
What is proposed
Direct measurement
Measure internal biological phase and distinguish its effects from clock time
With whatChange of environment or regimen
HowMeasure phase, randomize administration at different biological phases, and test controlled phase shifts using controlled sleep schedules
Possible result
Possible repeatable crossover in endocrine-versus-nonendocrine benefit as internal phase changes
From the recordThe relevant causal state is measured internal phase, not a permanent syndrome.
Scale or classification
Menopause syndrome classification
A classification that groups vasomotor, sleep, mood and metabolic problems into proposed menopause syndromes
Where this hypothesis actsWhen predicting treatment responses across biological phases during menopause
Hypotheses on this target 5- Telling states apart5
- Direct measurement
- Indicator replacement
What is proposed
Telling states apart
Test syndrome labels against a continuous circular phase-response model
With whatInstrument or assay
HowCompare a frozen circular phase-response model with syndrome labels for predicting held-out responses to randomized treatment timing
Possible result
Expected better prediction of held-out treatment response from internal phase than from syndrome labels
From the recordA frozen circular phase-response model then predicts held-out treatment response better than syndrome labels.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
A treatment that helps with menopause, the end of menstrual cycles, might work differently at different points in the body's daily cycle. The unexpected move is to explain apparent treatment-response groups as changing positions on that cycle rather than permanent kinds of patient. This is a proposal generated by the pipeline, not a measured result.
- Internal biological phase is proposed to change how strongly tissues respond to hormone-based and other treatments.
- Changing tissue responsiveness is proposed to reverse which treatment provides greater benefit at different biological phases.
- Weaker daily variation is proposed to make treatment timing and assessment by ordinary clock time particularly misleading.
- A participant moving through the biological cycle is therefore proposed to move between apparent response groups while inherited makeup, treatment history and menopause stage remain constant.
A shop can look reliably open or reliably closed if every visit happens at the same hour. Moving its opening schedule changes what a visit finds, even though it is still the same shop.
Where the picture breaks: Biological responsiveness need not switch simply between open and closed. The picture does not explain weaker daily variation or establish that two treatments exchange their relative benefits.
- Master questionstep 01 of 04
Understanding menopause syndromes, patterns of problems grouped together around menopause, is intended to inform research on radically extending lifespan.
Rests on: The goal assumes that understanding these patterns could provide knowledge relevant to extending life.
AssumptionThe supplied material does not establish that discovering menopause syndromes would identify ways to extend lifespan.
- Goal pillarstep 02 of 04
The intended outcome combines validated identification of menopause syndromes with a protocol for an intervention that produces lasting lifespan benefits.
Rests on: The master question explicitly connects discovering menopause syndromes with radical lifespan extension; this stage makes that ambition an intended research outcome.
Stated in the chain - Gap questionstep 03 of 04
Apparent menopause groups could be distinct biological types or changing states shaped by menopause stage and treatment. Competing ways of grouping participants would be judged by predictions made before responses to randomly assigned hormone-based and other interventions are observed.
Rests on: The goal calls for validated syndrome discovery; this stage makes prediction of treatment response the proposed basis for that validation.
Stated in the chain - Hypothesisstep 04 of 04
Internal biological phase is proposed to control how tissues respond to treatment. Reduced circadian amplitude, the size of changes across the roughly daily biological cycle, is proposed to make ordinary clock time misleading, so one participant could appear to change response group without changes in inherited makeup, treatment history or menopause stage.S1S2
Rests on: Two screened sources support the narrower background of weakened daily variation. S1, in Journal of Sleep Research (2025), reports dampened daily variation in electrical brain activity after menopause, but does not test treatment responsiveness. S2, available only as an abstract from The Journal of Clinical Endocrinology and Metabolism (1990), reports reduced daily and pulse variation in dehydroepiandrosterone, a hormone, in older postmenopausal women compared with younger cycling women, without changed daily timing; it does not establish phase-dependent treatment response.
Supported by literature
What is carried, and what is not. Two screened sources speak to one background feature: reduced daily variation after menopause. Neither establishes that biological phase controls treatment preference, that ordinary clock time misclassifies responses, or that the proposed sequence holds end to end; the literature support assigned to the hypothesis is limited to that background.
Where the reasoning is carried by something unstated · 1
- Master question. The supplied material does not establish that discovering menopause syndromes would identify ways to extend lifespan.
How a result here could mislead · 3
- Changing symptom reports across the day could be mistaken for changing bodily treatment response. What closes it: Measured bodily outcomes must accompany reports, and the required size of a meaningful phase-dependent difference must be fixed before testing. The proposal rejects a reporting-only effect but supplies no numerical criterion.
- A response following a controlled sleep schedule could be credited to internal phase even if it follows ordinary clock time or another consequence of the schedule. What closes it: Internal phase must be measured, and the design must distinguish movement with biological phase from movement with ordinary clock time while accounting for sleep changes. The supplied specification does not detail those controls.
- Effects persisting from an earlier treatment could look like a phase-dependent reversal, while a treatment acting too slowly could conceal a real reversal. What closes it: Treatment effects must develop rapidly enough for the comparison, and treatment order and residual effects must be addressed separately from shifting biological phase. The proposal requires a washout, a period for earlier treatment effects to subside, but does not specify how adequate recovery would be verified.
What would make this wrong. Under a design that verifies different internal phases, uses treatments acting rapidly enough, and addresses residual treatment effects, no meaningful phase-dependent change in relative treatment benefit would reject the hypothesis as specified. So would a change confined to reporting rather than measured bodily responses. A response pattern remaining tied to ordinary clock time after internal phase shifts would contradict the proposed internal-phase explanation. The supplied material does not define the numerical boundary for a meaningful effect.
What it would change. If the prediction held, menopause treatment selection would need to account for measured biological phase, and apparently stable syndrome labels could lose predictive value against a model that follows the daily cycle. That would change how the master question's proposed syndromes are discovered and validated. It would still not establish durable benefits across treatments and outcomes, or any extension of lifespan.
Sources read · 2
Dampened circadian amplitude of EEG power in women after menopause. · Journal of sleep research · 2025
“Furthermore, the dampened circadian variation of delta, theta and sigma power along with previous findings (Perez‐Medina‐Carballo et al., ) support the hypothesized weakened circadian signal promoting sleep in older women.”
Does not settle: This source does not test whether measured internal biological phase determines response to endocrine or nonendocrine treatments, whether treatment response types vary continuously with phase, whether reduced circadian amplitude makes clock-time dosing or assessment misleading, or whether an individual changes apparent response type when biological phase changes.
Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20-desmolase enzymatic activity. · The Journal of clinical endocrinology and metabolism · 1990
“Thus, compared to NCW, the decline of circulating DHEA level in PMW was expressed by attenuations of pulse amplitude and circadian amplitude, without changes in the timing of the circadian rhythm or pulse frequency.”
Does not settle: The source establishes reduced DHEA circadian and pulse amplitude in older postmenopausal women compared with younger cycling women, but does not test whether measured internal phase gates tissue or treatment responsiveness, whether clock-time dosing or assessment is misleading, whether response types vary continuously with phase, or whether an individual changes apparent response type as biological phase changes.
The gap this hypothesis explains
Two established results predict opposite outcomes, and both cannot be right.
Do menopause symptom groups predict different treatment effects, or reflect gradual changes with stage and treatment?
Original wording · exactly as the pipeline generated it
Do menopause syndromes represent distinct causal response types, or continuous states shaped by stage and treatment, when competing classifications prospectively predict responses to randomized endocrine and nonendocrine perturbations?
What this question is asking
The question asks whether patterns of symptoms around menopause identify genuinely different kinds of treatment response or describe changing positions along a continuum. It compares classifications that place people into separate groups with classifications that describe degrees of symptoms or states that can change over time. The proposed comparison asks whether these classifications predict responses to randomly assigned treatments that act through hormones and treatments that act through other routes. The pipeline assumes that evidence already supports competing representations, but the supplied sources establish only that researchers have identified statistical profiles. The requested standard is that definitions fixed beforehand work in independent populations and improve treatment selection over repeated follow-up.
- Menopause and menopausal stage
- Menopause is the end of menstrual periods associated with the end of ovarian reproductive function. Menopausal stage describes a person's position in the transition around that event; the question asks whether this position helps explain changing symptoms and treatment responses.
- Menopause syndrome or symptom profile
- A pattern of symptoms considered together. Calling a pattern a syndrome or profile does not itself establish a separate biological condition or a distinct response to treatment.
- Categorical classification
- A system that assigns observations or people to separate groups. Here, the issue is whether the boundaries between symptom groups predict meaningful differences in treatment effects.
- Dimensional or continuous representation
- A description using degrees along one or more scales instead of only separate group labels. The question asks whether such gradual differences explain treatment responses better than group membership.
- Hidden state
- An underlying condition inferred from measured observations rather than observed directly. A model can allow that state to change over time, but the supplied excerpts do not establish evidence for such transitions.
- Latent class analysis
- A statistical method that infers groups from patterns in measured data. A group identified by this method is a statistical result, not by itself proof of a separate cause or treatment-response type.
- Causal treatment-response type
- A group defined by how an intervention changes an outcome, rather than only by symptoms observed without that intervention. The question asks whether menopause symptom groups identify differences of this kind.
- Randomized endocrine and nonendocrine perturbations
- Interventions assigned by chance, with some acting through the hormone system and others through other routes. A perturbation means an imposed change used to observe a response; random assignment helps separate treatment effects from pre-existing differences between groups.
- Prospective prediction and longitudinal follow-up
- Prospective prediction specifies an expected outcome before it is observed. Longitudinal follow-up repeatedly observes the same people over time, allowing predictions to be assessed as symptoms and circumstances change.
- Locked phenotype definitions
- Rules for identifying observable characteristics or symptom patterns that are fixed before their predictive performance is assessed. Fixing the rules prevents the classification from being redefined to fit the outcomes being used to assess it.
- Externally reproducible eligibility
- The ability of the same classification rules to produce consistent qualification decisions when applied in independent populations. Here, eligibility concerns who would be included in a treatment or study group.
- Clinically meaningful incremental prediction
- An improvement in prediction beyond information already available that is large enough to matter for treatment decisions. The supplied material does not define the required improvement.
- Follicle-stimulating hormone and luteinizing hormone
- Hormones involved in regulating ovarian reproductive activity. S6 uses their measured levels, together with menstrual patterns, to help classify menopausal status.
- Depressive-symptom score
- A numerical summary of measured depression-related symptoms. S8 groups the ways these scores change over time; those trajectories do not themselves measure treatment effects.
Categorical and hidden-state approaches coexist with dimensional evidence, but none establishes distinct causal treatment-response classes; competing representations may imply different eligibility decisions.
The premise concerns ways of organizing menopause-related measurements: separate symptom groups, underlying states inferred from observations, and positions along continuous scales. It assumes that existing evidence supports these alternatives while leaving unresolved whether they identify different treatment effects. If that assumption holds, comparing their predictions could distinguish useful treatment-selection information from differences in how symptoms are described.
S5, S7 and S8 support the narrower claim that statistical methods have been used to identify symptom profiles. S6 also uses a statistical grouping method, but to determine menopausal status from hormone measurements and menstrual patterns. The supplied excerpts do not establish evidence for continuous alternatives or models of transitions between hidden states, show conflicting eligibility decisions, or support a literature-wide claim that no causal treatment-response classes have been established. Only four abstracts are represented, so the broader premise remains insufficiently assessed.S5S6S7S8
The same question asked without the part nothing read establishes:
- Do classifications using separate menopause symptom groups or continuous symptom measures better predict responses to randomly assigned hormone-based and other treatments?
- Do menopause symptom profiles predict treatment effects beyond information about menopausal stage and treatment history?
- Separate groups predict different treatment effects If fixed group definitions reproducibly distinguish the effects of randomly assigned treatments, group membership would provide information about which treatment produces which response. Group-based eligibility could then be informative, provided the distinctions improve prediction enough to matter for treatment decisions.
- Responses vary continuously with stage and treatment If treatment effects change gradually with symptom measurements and menopausal stage, discrete labels would divide a continuous pattern. Treatment selection based on rigid boundaries could lose information about response differences within each group and similarities across its boundaries.
- Neither representation improves treatment prediction If neither classification adds useful information about treatment effects, describing symptom patterns would not establish a basis for choosing between treatments. Eligibility decisions derived from those classifications would lack the predictive justification sought by the question.
A symptom classification can influence who qualifies for a treatment and which treatment is selected. That use requires a connection between the classification and differences in treatment effects, beyond simply describing symptoms. If symptom groups identify different treatment effects, their boundaries could carry information relevant to treatment selection. If responses instead vary gradually or change with stage and treatment, fixed group boundaries could separate people whose responses are similar or combine people whose responses differ. The supplied evidence does not establish which chain applies.
RL-1 categorical and hidden-state approaches coexist with RL-2 dimensional evidence; none establishes distinct causal treatment-response classes.
Locked phenotype definitions yield externally reproducible eligibility and clinically meaningful incremental prediction across longitudinal follow-up.
Competing representations may imply different eligibility decisions, but no prospective perturbation comparison determines which distinctions improve intervention selection.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Menopause response types are positions on a continuous circadian cycle: internal biological phase gates tissue responsiveness to endocrine and nonendocrine inputs. Reduced circadian amplitude makes clock-time dosing and assessment particularly misleading. A participant can therefore change apparent response type when biological phase changes, although genotype, treatment history and menopausal stage remain constant. The relevant causal state is measured internal phase, not a permanent syndrome.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
For interventions with sufficiently rapid pharmacodynamics, randomized administration at different measured biological phases produces a repeatable crossover in endocrine-versus-nonendocrine benefit. A controlled phase shift moves the response curve with internal phase rather than civil clock time. A frozen circular phase-response model then predicts held-out treatment response better than syndrome labels. No meaningful phase interaction, or an interaction confined to reporting rather than objective physiology, rejects this hypothesis.
Would tell it apart from at least one rival. The prediction specifies observable phase-dependent comparisons, comparative predictive performance, and an explicit rejection condition. No rival prediction is supplied. A paper already fetched for this hypothesis bears on it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Circadian laboratories can measure phase and use controlled sleep schedules. Long-acting endocrine regimens cannot resolve acute phase effects and require a different design. Initial tests should use suitable reversible outcomes, with phase shifts and treatment washout handled separately.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
For interventions with sufficiently rapid pharmacodynamics, randomized administration at different measured biological phases produces a repeatable crossover in endocrine-versus-nonendocrine benefit. A controlled phase shift moves the response curve with internal phase rather than civil clock time. A frozen circular phase-response model then predicts held-out treatment response better than syndrome labels. No meaningful phase interaction, or an interaction confined to reporting rather than objective physiology, rejects this hypothesis.
- Rival 01 of 04What would separate them
An initial hormone challenge may create menopause response types through lasting gene priming predicts: Randomize an initial endocrine exposure or matched control, allow verified exposure clearance and recovery of prespecified clinical baselines, then independently randomize endocrine versus nonendocrine treatment. The initial exposure changes the later treatment contrast for objective physiological outcomes, with a persistent transcriptional recall signature preceding that change. A reproducible initial-exposure-by-later-treatment interaction supports this hypothesis; its absence within a prespecified clinically meaningful equivalence margin favors the other rivals. In matched cell models, erasing the candidate priming mark must abolish altered recall without changing genotype or current receptor exposure.
- What would separate them
Random physiological fluctuations may create apparent menopause response types predicts: A frozen first-passage model predicts held-out event waiting times, return times and treatment effects using estimated fluctuation variance and relaxation rate, while fixed syndrome labels add no clinically meaningful treatment-selection value. Under a bounded randomized mild thermal input with equal mean but different temporal variance, event rates change as predicted by the model without persistent reassignment after the input ends. Stable person-specific classes, enduring priming effects, or phase-locked reversals unexplained by the stochastic model would reject it as the dominant explanation.
- Rival 03 of 04What would separate them
Reporting and selection may create apparent menopause syndromes from partly independent disorders predicts: In an externally recruited cohort with objective endpoints and randomized endocrine and nonendocrine assignments, each component's baseline severity and established clinical modifiers predict its response, but a frozen syndrome label supplies no additional treatment interaction within a prespecified equivalence margin. Residual objective responses across components show no reproducible shared response factor. Changing questionnaire framing alters category assignment without changing objective treatment effects. Reproducible shared stochastic dynamics, genotype-defined response classes, molecular priming or phase-dependent cross-domain treatment rankings would defeat this explanation.
- Rival 04 of 04What would separate them
Inherited regulatory combinations may create distinct menopause treatment-response types predicts: A prespecified regulatory-genotype classifier predicts a reproducible endocrine-versus-nonendocrine treatment interaction across stage transitions and independent cohorts, beyond flexible continuous baseline models. In matched isogenic cells, editing the implicated variant combination reverses the relevant endocrine transcriptional response at equal exposure; sham editing does not. If genotype effects are only smooth, weak modifiers without reproducible treatment-ranking partitions, this discrete-type hypothesis fails.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. 6 paper(s) already retrieved for this hypothesis carry its prediction’s terms. Reading them comes before running anything. Already retrieved: Efficacy of Combining Kegel Exercises with EMS-Based Pelvic Floor Muscle Electrostimulation in Postmenopausal Women with Involuntary Urinary Leakage.; Women living with diabetes: Overlooked and under-recognised, the psychosocial impact.; Association of reproductive factors and chronic kidney disease in postmenopausal women: results from the U.S. National Health and Nutrition Examination Survey 1999 - 2020..
6 papers retrieved around this hypothesis
- Exploring working conditions and job stability of midwives in Spain: results from a cross-sectional national survey.PMID 42310573 · full_text · 62,683 characters stored
- Association of reproductive factors and chronic kidney disease in postmenopausal women: results from the U.S. National Health and Nutrition Examination Survey 1999 - 2020.PMID 42128617 · full_text · 56,698 characters stored
- Sex-specific trajectories of nonlinear immune aging at single-cell level.PMID 42764338 · full_text · 115,453 characters stored
- Efficacy of Combining Kegel Exercises with EMS-Based Pelvic Floor Muscle Electrostimulation in Postmenopausal Women with Involuntary Urinary Leakage.PMID 42187519 · full_text · 46,156 characters stored
- Women living with diabetes: Overlooked and under-recognised, the psychosocial impact.PMID 42316786 · full_text · 54,835 characters stored
- Risk Factors for Estrogen Receptor Subtype-Specific Contralateral Breast Cancer in Women Under Age 55 Years.PMID 42563563 · full_text · 71,864 characters stored
0 citation handles extracted; 1 Europe PMC search run; 8 records examined; 6 sources stored for enrichment, 6 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.